Skip to main content
SpringerLink
Log in

Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study

  • Original Article
  • Published:
Glycoconjugate Journal Aims and scope Submit manuscript

Abstract

In non-diabetics, low levels of soluble receptor for advanced glycations end products (sRAGE) associate with an increased risk of development of diabetes, cardiovascular afflictions, or death. The majority of studies in non-diabetics report an inverse relationship between measures of obesity, cardiometabolic risk factors and sRAGE and/or endogenous secretory RAGE (esRAGE) levels. To elucidate whether this inconsistency is related to the metabolically healthy obese phenotype, or a different impact of the risk factors in presence and absence of obesity, we analyzed data from 2206 apparently healthy adolescents (51 % girls) aged 15-to-19 years. The association of sRAGE levels with soluble vascular adhesion protein-1/semicarbazide sensitive amine oxidase (sVAP-1/SSAO) was also investigated. Centrally obese, including metabolically healthy, adolescents present significantly lower sRAGE and esRAGE, but not sVAP-1, levels in comparison with their lean counterparts. An increasing number of cardiometabolic risk factors did not associate with significant changes in sRAGE, esRAGE or sVAP-1 levels either in lean or in obese subjects. In multivariate analyses, WHtR, hsCRP, markers of glucose homeostasis, renal function, adiponectin, and sVAP-1 associated significantly with sRAGE and esRAGE. SVAP-1 correlated significantly with glycemia, adiponectin, hsCRP, and sRAGE. Thus, in adolescents, a decline in sRAGE and esRAGE precedes the development of metabolic syndrome. When combined, standard and non-standard cardiometabolic risk factors explain only minor proportion in a variability of sRAGE and esRAGE (8 %–11 %); or sVAP-1 (12 %–20 %). Elucidation of pathogenetic mechanisms underlying early decline in sRAGE and esRAGE levels in obese adolescents and their clinical impact with regard to future cardiometabolic health requires further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thorpe S.R., Baynes J.W.: Role of the maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging. 9, 69–77 (1996)

    Article  CAS  PubMed  Google Scholar 

  2. Miyata T., Kurokawa K., van Ypersele de Strihou C.: Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int. Suppl. 76, S120–S125 (2000)

    Article  CAS  PubMed  Google Scholar 

  3. Stern D., Yan S.D., Yan S.F., et al.: Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev. 54, 1615–1625 (2002)

    Article  CAS  PubMed  Google Scholar 

  4. Bierhaus A., Humpert P.M., Morcos M., et al.: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 83(876–86), (2005)

  5. Schmidt A.M., Yan S.D., Yan S.F., et al.: The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta. 1498, 99–111 (2000)

    Article  CAS  PubMed  Google Scholar 

  6. Brett J., Schmidt A.M., Yan S.D., et al.: Survey of the distribution of a newly characterized receptor for advanced glyaction end-products in tissues. Am. J. Pathol. 143, 1699–1712 (1993)

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Sessa L., Gatti E., Zeni F., et al.: The receptor for advanced glycation end-products (RAGE) is only present in mammals and belongs to a family of cell adhesion molecules (CAMs). PLoS ONE. 9, e86903 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gaens K.H.J., Goossens G.H., Niessen P.M., et al.: N-epsilon-(carboxymethyl) lysine- receptor for advanced glycation end product Axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler. Thromb. Vasc. Biol. 34, 1199–1208 (2014)

    Article  CAS  PubMed  Google Scholar 

  9. Raucci A., Cugusi S., Antonelli A., et al.: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22, 3716–3727 (2008)

    Article  CAS  PubMed  Google Scholar 

  10. Zhang L., Bukulin M., Kojro E., et al.: Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 283, 35507–35516 (2008)

    Article  CAS  PubMed  Google Scholar 

  11. Hudson B.I., Carter A.M., Harja E., et al.: Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22, 1572–1580 (2008)

    Article  CAS  PubMed  Google Scholar 

  12. Yamagishi S.: Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013; 62:2116-2121. Diabetes. 62, E26–E26 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Koyama H., Shoji T., Yokoyama H., et al.: Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 2587–2593 (2005)

    Article  CAS  PubMed  Google Scholar 

  14. Yamagishi S., Adachi H., Nakamura K., et al.: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 55, 1227–1231 (2006)

    Article  CAS  PubMed  Google Scholar 

  15. Accacha S., Rosenfeld W., Jacobson A., et al.: Plasma advanced glycation end products (AGEs). Receptors for AGEs and Their Correlation with Inflammatory Markers in Middle School-Age Children. Horm Res Paediatr. 80, 318–327 (2013)

    CAS  PubMed  Google Scholar 

  16. He C.T., Lee C.H., Hsieh C.H., et al.: Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents. Int. J. Endocrinol. 2014(657607), (2014)

  17. Šebeková K., Krivošíková Z., Gajdoš M.: Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects. Clin. Chem. Lab. Med. 52, 139–149 (2014)

    PubMed  Google Scholar 

  18. Momma H., Niu K., Kobayashi Y., et al.: Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study. Diabetol. Metab. Syndr. 6, 33 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hagen I., Schulte D.M., Müller N., et al.: Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine. 73, 265–269 (2015)

    Article  CAS  PubMed  Google Scholar 

  20. Rowisha, M., El-Batch, M., El Shikh, T. et al.: Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks. Pediatr Res. Epub ahead of print (2006)

  21. Mahajan N., Malik N., Bahl A., et al.: Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. Mol. Cell. Biochem. 330, 201–209 (2009)

    Article  CAS  PubMed  Google Scholar 

  22. Šebeková K., Somoza V., Jarčušková M., et al.: Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int. J. Pediatr. Obes. 4, 112–118 (2009)

    Article  PubMed  Google Scholar 

  23. Basta G., Sironi A.M., Lazzerini G., et al.: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100 A12 protein. J. Clin. Endocrinol. Metab. 91, 4628–4634 (2006)

    Article  CAS  PubMed  Google Scholar 

  24. Selvin E., Halushka M.K., Rawlings A.M., et al.: sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 62, 2116–2121 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chiang K.H., Huang P.H., Huang S.S., et al.: Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients. Coron. Artery Dis. 20, 267–273 (2009)

    Article  PubMed  Google Scholar 

  26. Falcone C., Emanuele E., D'Angelo A., et al.: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25, 1032–1037 (2005)

    Article  CAS  PubMed  Google Scholar 

  27. Deng Y.L., Yu P.H.: Assessment of the deamination of aminoacetone, an endogenous substrate for semicarbazide-sensitive amine oxidase. Anal. Biochem. 270, 97–102 (1999)

    Article  CAS  PubMed  Google Scholar 

  28. Rabbani N., Thornalley P.J.: Glyoxalase in diabetes, obesity and related disorders. Semin. Cell Dev. Biol. 22, 309–317 (2011)

    Article  CAS  PubMed  Google Scholar 

  29. Abella A., Garcia-Vicente S., Viguerie N., et al.: Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia. 47, 429–438 (2004)

    Article  CAS  PubMed  Google Scholar 

  30. Brochu M., Tchernof A., Dionne I.J., et al.: What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab. 86, 1020–1025 (2001)

    CAS  PubMed  Google Scholar 

  31. Gurecká R., Koborová I., Šebek J., et al.: Presence of cardiometabolic risk factors is not associated with microalbuminuria in 14-to-20-years old Slovak adolescents: a cross-sectional. Population Study. PLoS One. 10, e0129311 (2015)

    Article  PubMed  Google Scholar 

  32. Lanati N., Emanuele E., Brondino N., et al.: Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr. Vasc. Pharmacol. 8, 86–92 (2010)

    Article  CAS  PubMed  Google Scholar 

  33. Katz A., Nambi S.S., Mather K., et al.: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85, 2402–2410 (2000)

    Article  CAS  PubMed  Google Scholar 

  34. Dobiasova M., Frohlich J.: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin. Biochem. 34, 583–588 (2001)

    Article  CAS  PubMed  Google Scholar 

  35. Schwartz G., Munoz A., Schneider M., et al.: New creatinine-based formulas to estimate GFR in children with chronic kidney disease (CKD). Pediatr. Nephrol. 22, 1457–1457 (2007)

    Article  Google Scholar 

  36. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 39(suppl 1), S1–266 (2002)

  37. McCarthy H.D., Ashwell M.: A study of central fatness using waist-to-height ratios in UK children and adolescents over two decades supports the simple message - 'keep your waist circumference to less than half your height'. Int J Obesity. 30, 988–992 (2006)

    Article  CAS  Google Scholar 

  38. Zimmet P., George K., Alberti M.M., et al.: The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr. Diabetes. 8, 299–306 (2007)

    Article  PubMed  Google Scholar 

  39. Norata G.D., Garlaschelli K., Grigore L., et al.: Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr. Metab. Cardiovasc. Dis. 19, 129–134 (2009)

    Article  CAS  PubMed  Google Scholar 

  40. Vazzana N., Guagnano M.T., Cuccurullo C., et al.: Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J. Clin. Endocrinol. Metab. 97, E1726–E1730 (2012)

    Article  CAS  PubMed  Google Scholar 

  41. de Giorgis T., D'Adamo E., Giannini C., et al.: Could receptors for advanced glycation end products Be considered cardiovascular risk markers in obese children? Antiox Redox Signal. 17, 187–191 (2012)

    Article  Google Scholar 

  42. Chiavaroli V., D'Adamo E., Giannini C., et al.: Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care. 35, 1361–1363 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Brickey S.R., Ryder J.R., McClellan D.R., et al.: Soluble receptor for advanced glycation end products independently predicts cardiometabolic syndrome in Latino youth. Pediatr. Diabetes. 15, 403–407 (2014)

    Article  CAS  PubMed  Google Scholar 

  44. Roberson L.L., Aneni E.C., Maziak W., et al.: Beyond BMI: the "metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality - a systematic review. BMC Public Health. 14, 14 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  45. Kramer C.K., Zinman B., Retnakaran R.: Are metabolically healthy overweight and obesity benign conditions? A Systematic Review and Meta-analysis. Ann Intern Med. 159, 758–769 (2013)

    PubMed  Google Scholar 

  46. Mangge H., Almer G., Truschnig-Wilders M., et al.: Inflammation, adiponectin, obesity and cardiovascular risk. Curr. Med. Chem. 17, 4511–4520 (2010)

    Article  CAS  PubMed  Google Scholar 

  47. Davis K.E., Prasad C., Vijayagopal P., et al.: Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults. Nutr. Res. 34, 478–485 (2014)

    Article  CAS  PubMed  Google Scholar 

  48. Tahara N., Yamagishi S., Matsui T., et al.: Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc. Ther. 30, 42–48 (2012)

    Article  CAS  PubMed  Google Scholar 

  49. Germánová A., Koucký M., Hájek Z., et al.: Soluble receptor for advanced glycation end products in physiological and pathological pregnancy. Clinical Biochemistry. 43, 442–446 (2010)

    Article  PubMed  Google Scholar 

  50. Kalousová M., Hodková M., Kazderová M., et al.: Soluble receptor for advanced glycation end products in patients with decreased renal function. Am. J. Kidney Dis. 47, 406–411 (2006)

    Article  PubMed  Google Scholar 

  51. Nakamura K., Adachi H., Matsui T., et al.: Independent determinants of a soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism. 58, 421–425 (2009)

    Article  CAS  PubMed  Google Scholar 

  52. Pruijm M., Ponte B., Vollenweider P., et al.: Not all inflammatory markers are linked to kidney function: results from a population-based study. Am. J. Nephrol. 35, 288–294 (2012)

    Article  CAS  PubMed  Google Scholar 

  53. Lam J.K.Y., Wang Y., Shiu S.W.M., et al.: Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet. Med. 30, 702–709 (2013)

    Article  CAS  PubMed  Google Scholar 

  54. Lee A.C.H., Lam J.K.Y., Shiu S.W.M., et al.: Serum level of soluble receptor for advanced glycation end products is associated with a disintegrin and metalloproteinase 10 in type 1 diabetes. PLoS ONE. 10, e0137330 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  55. Sullivan C.M., Futers T.S., Barrett J.H., et al.: RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study. Diab Vasc Dis Res. 2, 42–44 (2005)

    Article  PubMed  Google Scholar 

  56. Gaens, K. H. J., van der Kallen, C. J. H., van Greevenbroek, M. M. J. et al.: Receptor for advanced glycation end product polymorphisms and type 2 diabetes - the CODAM study, maillard reaction: recent advances in food and biomedical sciences annals of the New York Academy of Sciences E. Schleicher, V. Somoza and P. Shieberle, (eds.), pp. 162–165, New York: The New York Academy of Sciences (2008)

  57. Jang Y., Kim J.Y., Kang S.M., et al.: Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism. 56, 199–205 (2007)

    Article  CAS  PubMed  Google Scholar 

  58. Boor P., Celec P., Klenovicsová K., et al.: Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers. Clin. Chim. Acta. 411, 1034–1040 (2010)

    Article  CAS  PubMed  Google Scholar 

  59. Schmidt A.M., Stern D.: Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep. 5, 430–436 (2000)

    Article  Google Scholar 

  60. Bošanská L., Michalský D., Lacinova Z., et al.: The influence of obesity and different fat depots on adipose tissue Gene expression and protein levels of cell adhesion molecules. Physiol. Res. 59, 79–88 (2010)

    PubMed  Google Scholar 

  61. Desideri G., De Simone M., Iughetti L., et al.: Early activation of vascular endothelial cells and platelets in obese children. J. Clin. Endocrinol. Metab. 90, 3145–3152 (2005)

    Article  CAS  PubMed  Google Scholar 

  62. Glowinska B., Urban M., Peczynska J., et al.: Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism. 54, 1020–1026 (2005)

    Article  CAS  PubMed  Google Scholar 

  63. Nordquist, J., (2002) “Semicarbazide-sensitive amine oxidase and vascular complications in diabetes mellitus. Biochemical and molecular aspects,” Medical Faculty, Acta Univesitatis Upsaliensis Uppsala, 51.

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Institute of Molecular BioMedicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia

    Radana Gurecká, Ivana Koborová, Melinda Csongová & Katarína Šebeková

  2. Faculty of Medicine, Institute of Medical Physics, Biophysics, Informatics and Telemedicine, Comenius University, Bratislava, Slovakia

    Radana Gurecká

  3. Slovak Academy of Sciences, Institute of Materials & Machine Mechanics, Bratislava, Slovakia

    Jozef Šebek

Authors
  1. Radana Gurecká
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivana Koborová
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melinda Csongová
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jozef Šebek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katarína Šebeková
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katarína Šebeková.

Ethics declarations

Funding

The Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and the Slovak Academy of Sciences, grant No. 1/0637/13 and the Slovak Research and Development Agency, grant No. 0447–12. The authors wish to thank all those who put their effort toward the accomplishment of the “Respect for Health” study.

Conflict of interests

Nothing to declare

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gurecká, R., Koborová, I., Csongová, M. et al. Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study. Glycoconj J 33, 599–606 (2016). https://doi.org/10.1007/s10719-016-9696-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10719-016-9696-9

Keywords

Search

Navigation